Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Safety signals in specific populations, insufficient efficacy in certain endpoints, or manufacturing challenges could all slow progress
Safety and immunogenicity of the -synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Safflower yellow reduces DEN-induced hepatocellular carcinoma by enhancing liver immune infiltration through promotion of collagen degradation and modulation of gut microbiota
Tirzepatide also provided superior improvements in HbA1c and overall glycemic control
US$ 22.98
US$ 25.95
US$ 27.24
US$ 24.15
/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820182.png)
US$ 22.02
US$ 21.33
US$ 22.15
US$ 26.50
US$ 23.84
US$ 23.18
US$ 22.98
